顺铂与多西紫杉醇同期放化治疗ⅡB～ⅣA期宫颈癌30例初步疗效分析

Effect Analysis of Cisplatin and Docetaxel in Concurrent Chemotherapy and Radiotherapy in Stage ⅡB～ⅣA Cervical Cancer:A Report of 30 Cases

目的探讨ⅡB～ⅣA期宫颈癌低毒高效的放化联合治疗方式。方法 30例患者随机分为每周顺铂同期放化疗组(18例)和多西紫杉醇同期放化疗组(12例)。顺铂同期放化疗组化疗用药顺铂30mg/(m2?周),每周放疗的第1天同步静脉滴注,连续6周;多西紫杉醇同期放化疗组化疗用药多西紫杉醇25mg/(m2?周),每周放疗的第1天同步静脉滴注,多西紫杉醇常规抗过敏预处理,连续6周。结果两组患者总有效率91%vs83%,临床获益率91%vs89%,差异无统计学意义(P>0.05);两组随访12个月无进展生存率(PFS)比较83%vs78%,总生存率(OS)100%vs94%,差异无统计学意义(P>0.05);但多西紫杉醇同期放化组较顺铂同期放化组治疗无论在血液系统毒副反应和非血液系统毒副反应方面都明显降低(P<0.05)。结论多西紫杉醇同期放化疗可取得不亚于顺铂同期放化治疗的疗效,但多西紫杉醇方式患者的毒副反应明显降低。

Objective To investigate the more effective and low toxicity chemotherapy options of concurrent chemotherapy and radiotherapy for stage ⅡB～ⅣA cervical cancer. Methods Totally 30 cases with stage ⅡB～ⅣA cervical cancer who were intended to be treated by concurrent chemotherapy and radiotherapy were randomized into two groups： cisplatin groups（n=18） and docetaxel groups（n=12）.The chemotherapy regimen given accordingly to cisplatin group at a dose of 30mg/（m2·w） for 6 cycles and docetaxel group at a dose of 25mg/（m2·w） for 6 cycles under the conditions of anti-allergic management. Both groups received external radiotherapy Results The effective rate and clinical benef its rate were 91% vs 83% and 91% vs 89% accordingly （P0.05 ）.The 12 months disease-free survival and overall survival were 83% vs 78%and100% vs 94% accordingly （P0.05 ）. Howerever docetaxel group show a significant alleviated hematologic or non-hematologic toxicity than cisplatin group （P0.05）.Conclusion Docetaxel can reach the identical effection than cisplatin group with the obvious lower side-effect.